Journal of Pharmacokinetics and Pharmacodynamics

Papers
(The H4-Index of Journal of Pharmacokinetics and Pharmacodynamics is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies36
Population pharmacokinetic and pharmacodynamic model of propofol externally validated in Korean elderly subjects30
Application of different approaches to generate virtual patient populations for the quantitative systems pharmacology model of erythropoiesis30
Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases26
Advancing inclusive healthcare through PBPK modelling: predicting the impact of CYP genotypes and enzyme ontogenies on infant exposures of venlafaxine and its active metabolite O-desmethylvenlafaxine 25
Learning pharmacometric covariate model structures with symbolic regression networks22
Mixed effect estimation in deep compartment models: Variational methods outperform first-order approximations22
Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease16
Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials16
Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations16
Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of 15
Translational population target binding model for the anti-FcRn fragment antibody efgartigimod15
Current practices for QSP model assessment: an IQ consortium survey15
Early exposure-response modeling of an interferon-beta monoclonal antibody (dazukibart) in adults with dermatomyositis14
ADPO: automatic-differentiation-assisted parametric optimization14
Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses14
0.45341992378235